CTLT Stock Recent News

Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research

EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines announces appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent Director.

Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors that it entered a research license agreement with Catalent to evaluate certepetide as a payload in SMARTag dual-payload ADCs.

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its iRGD cyclic peptide candidate, using Catalent's SMARTag antibody-drug conjugate (ADC) platform. The research will focus on preclinical testing for diseases such as advanced solid tumors.

BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company has entered into a research license with Catalent, Inc. (“Catalent”) to evaluate, in a preclinical setting, the efficacy of Lisata's iRGD cyclic peptide product candidate, certepetide, as a payload used in the context of Catalent's SMARTag® antibody-drug conjugate (“ADC”) dual-payload technology platform for the treatment of difficult-to-treat-diseases, including advanced solid tumors.

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.

Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catalent , saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected.